[{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"CEL-SCI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Prestige BioPharma Pte Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TEV-56278","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"AlivaMab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"3","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ICELAND","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Assia Chemical Industries Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assia Chemical Industries Ltd \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Assia Chemical Industries Ltd \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Teva Pharmaceutical Industries \/ Mabxience","highestDevelopmentStatusID":"1","companyTruncated":"Teva Pharmaceutical Industries \/ Mabxience"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"}]

Find Oncology Clinical Drug Pipeline Developments & Deals by Teva Pharmaceutical Industries

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 28, 2024

                          Lead Product(s) : TEV-56278

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 04, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : Mabxience

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : mAbxience will lead the development and production of an anti PD-1 biosimilar and Teva will manage regulatory approvals and oversee commercialization of this oncology treatment.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 10, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Mabxience

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes, follicular lymphoma and marginal zone lymphoma.

                          Product Name : Lenalid

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 03, 2023

                          Lead Product(s) : Lenalidomide,Dexamethasone

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Natco Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Multikine (leukocyte interleukin) is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

                          Product Name : Multikine

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 09, 2022

                          Lead Product(s) : Interleukin 2,Cyclophosphamide,Indomethacin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : CEL-SCI

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Revlimid (lenalidomide capsules), a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, is first generic version available in 5mg, 10mg, 15mg, and 25mg strengths, in the United States...

                          Product Name : Lenalidomide-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 03, 2022

                          Lead Product(s) : Lenalidomide,Dexamethasone

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The programs will leverage the ADS discovery platform, which includes a suite of different immunization technologies that address challenging targets such as G-protein-coupled-receptors and high homology targets.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 14, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : AlivaMab

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          November 19, 2020

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : University of Cologne

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The partnership includes the exclusive rights for Teva Israel to commercialize Tuznue™ (trastuzumab) in Israel, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing pharmaceutical products to market...

                          Product Name : Tuznue

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          October 11, 2020

                          Lead Product(s) : Trastuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Prestige BioPharma Pte Ltd

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 08, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : Alvotech

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank